Advanced search
Publication Cover
Expert Review of Hematology Volume 6, 2013 - Issue 1
Submit an article Journal homepage
78
Views
3
CrossRef citations to date
0
Altmetric
Drug Profile

Pixantrone: merging safety with efficacy

Dionysios Papadatos-Pastos St George’s Healthcare NHS Trust, Blackshaw Road, London, SW17 0QT, UK
&
Ruth Pettengell St George’s Healthcare NHS Trust, Blackshaw Road, London, SW17 0QT, UK. [email protected]
Pages 25-33 | Published online: 10 Jan 2014

References

  • Fisher RI, Gaynor ER, Dahlberg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N. Engl. J. Med. 328(14), 1002–1006 (1993).
  • Gisselbrecht C, Glass B, Mounier N et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J. Clin. Oncol. 28(27), 4184–4190 (2010).
  • van Dalen EC, van der Pal HJ, Bakker PJ, Caron HN, Kremer LC. Cumulative incidence and risk factors of mitoxantrone-induced cardiotoxicity in children: a systematic review. Eur. J. Cancer 40(5), 643–652 (2004).
  • Velasquez WS, McLaughlin P, Tucker S et al. ESHAP – an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J. Clin. Oncol. 12(6), 1169–1176 (1994).
  • Jerkeman M, Leppä S, Kvaløy S, Holte H. ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma – the Nordic Lymphoma Group experience. Eur. J. Haematol. 73(3), 179–182 (2004).
  • Velasquez WS, Cabanillas F, Salvador P et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 71(1), 117–122 (1988).
  • Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 266(12), 1672–1677 (1991).
  • Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 32(2), 302–314 (1973).
  • Von Hoff DD, Layard MW, Basa P et al. Risk factors for doxorubicin-induced congestive heart failure. Ann. Intern. Med. 91(5), 710–717 (1979).
  • Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann. Oncol. 13(5), 699–709 (2002).
  • Cortés-Funes H, Coronado C. Role of anthracyclines in the era of targeted therapy. Cardiovasc. Toxicol. 7(2), 56–60 (2007).
  • Salvatorelli E, Menna P, Lusini M, Covino E, Minotti G. Doxorubicinolone formation and efflux: a salvage pathway against epirubicin accumulation in human heart. J. Pharmacol. Exp. Ther. 329(1), 175–184 (2009).
  • Batist G, Ramakrishnan G, Rao CS et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J. Clin. Oncol. 19(5), 1444–1454 (2001).
  • Macpherson N, Belch A, Taylor M, Sutherland J, Czaykowski P, Connors J. Liposomal encapsulated doxorubicin (Caelyx) in the treatment of relapsed aggressive non-Hodgkin’s lymphoma: a Phase II study. Leuk. Lymphoma 47(7), 1327–1332 (2006).
  • van Dalen EC, Caron HN, Dickinson HO, Kremer LC. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst. Rev. 2, 16(2) CD003917 (2008).
  • Balzarotti M, Santoro A, Tondini C, Fornier M, Bonadonna G. Activity of single agent vinorelbine in pretreated non-Hodgkin’s lymphoma. Ann. Oncol. 7(9), 970–972 (1996).
  • Germann N, Brienza S, Rotarski M et al. Preliminary results on the activity of oxaliplatin (L-OHP) in refractory/recurrent non-Hodgkin’s lymphoma patients. Ann. Oncol. 10(3), 351–354 (1999).
  • Fosså A, Santoro A, Hiddemann W et al. Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin’s lymphoma. J. Clin. Oncol. 17(12), 3786–3792 (1999).
  • Pfreundschuh M, Trümper L, Osterborg A et al.; MabThera International Trial Group. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 7(5), 379–391 (2006).
  • Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346(4), 235–242 (2002).
  • Wiernik PH, Lossos IS, Tuscano JM et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin’s lymphoma. J. Clin. Oncol. 26(30), 4952–4957 (2008).
  • Cheson BD, Bartlett NL, Vose JM et al. A Phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma. Cancer 118(12), 3128–3134 (2012).
  • Reichert JM. Antibody-based therapeutics to watch in 2011. MAbs 3(1), 76–99 (2011).
  • Denny WA, Wakelin LP. Kinetics of the binding of mitoxantrone, ametantrone and analogues to DNA: relationship with binding mode and anti-tumour activity. Anticancer Drug Des. 5(2), 189–200 (1990).
  • De Isabella P, Palumbo M, Sissi C et al. Topoisomerase II DNA cleavage stimulation, DNA binding activity, cytotoxicity, and physico-chemical properties of 2-aza- and 2-aza-oxide-anthracenedione derivatives. Mol. Pharmacol. 48(1), 30–38 (1995).
  • Zwelling LA, Mayes J, Altschuler E, Satitpunwaycha P, Tritton TR, Hacker MP. Activity of two novel anthracene-9,10-diones against human leukemia cells containing intercalator-sensitive or -resistant forms of topoisomerase II. Biochem. Pharmacol. 46(2), 265–271 (1993).
  • Evison BJ, Mansour OC, Menta E, Phillips DR, Cutts SM. Pixantrone can be activated by formaldehyde to generate a potent DNA adduct forming agent. Nucleic Acids Res. 35(11), 3581–3589 (2007).
  • Evison BJ, Bilardi RA, Chiu FC, Pezzoni G, Phillips DR, Cutts SM. CpG methylation potentiates pixantrone and doxorubicin-induced DNA damage and is a marker of drug sensitivity. Nucleic Acids Res. 37(19), 6355–6370 (2009).
  • Beggiolin G, Crippa L, Menta E et al. Bbr 2778, an aza-anthracenedione endowed with preclinical anticancer activity and lack of delayed cardiotoxicity. Tumori 87(6), 407–416 (2001).
  • Cavalletti E, Crippa L, Mainardi P et al. Pixantrone (BBR 2778) has reduced cardiotoxic potential in mice pretreated with doxorubicin: comparative studies against doxorubicin and mitoxantrone. Invest. New Drugs 25(3), 187–195 (2007).
  • Dawson LK, Jodrell DI, Bowman A et al. A clinical Phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly. Eur. J. Cancer 36(18), 2353–2359 (2000).
  • Jamal-Hanjani M, Pettengell R. Pharmacokinetic evaluation of pixantrone for the treatment of non-Hodgkin’s lymphoma. Expert Opin. Drug Metab. Toxicol. 7(11), 1441–1448 (2011).
  • Faivre S, Raymond E, Boige V et al. A Phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies. Clin. Cancer Res. 7(1), 43–50 (2001).
  • Borchmann P, Schnell R, Knippertz R et al. Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin’s lymphoma. Ann. Oncol. 12(5), 661–667 (2001).
  • Borchmann P, Morschhauser F, Parry A et al. Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin’s lymphomas. Haematologica 88(8), 888–894 (2003).
  • Borchmann P, Herbrecht R, Wilhelm M et al. Phase I/II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin lymphoma. Leuk. Lymphoma 52(4), 620–628 (2011).
  • Lim ST, Fayad L, Tulpule A et al. A Phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin’s lymphoma. Leuk. Lymphoma 48(2), 374–380 (2007).
  • Herbrecht R, MacDonald D, Weissinger F et al. CPOP-R versus CHOP-R as first-line therapy for diffuse large B-cell lymphoma (DLBCL): a Phase 2, randomized, open-label, multicenter study. Presented at: 53rd Annual Meeting of the American Society of Hematology (ASH). San Diego, CA, USA, 2011 (Abstract 1605).
  • Srokowski TP, Liebmann JE, Modiano MR et al. Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: Phase 1 study with a dose-expansion cohort. Cancer 117(22), 5067–5073 (2011).
  • McLaughlin P, Grillo-López AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16(8), 2825–2833 (1998).
  • Rummel MJ, Niederle N, Maschmeyer G et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent and mantle-cell lymphomas: final results of a randomized Phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood 114, Abstract 405 (2009).
  • Wang M, Fayad L, Wagner-Bartak N et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a Phase 1/2 clinical trial. Lancet Oncol. 13(7), 716–723 (2012).
  • Santoro A, Voglova J, Gabrail N et al. Comparative trial of BBR 2778 (pixantrone) + rituximab vs single agent rituximab in the treatment of relapsed/refractory indolent non-Hodgkin’s lymphoma (NHL). Presented at: ASCO Annual Meeting Proceedings. Atlanta, GA, USA, 2006 (Abstract 7578).
  • Pettengell R, Coiffier B, Narayanan G et al. Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a Phase 3, multicentre, open-label, randomised trial. Lancet Oncol. 13(7), 696–706 (2012).
  • Karussis D, Biermann LD, Bohlega S et al.; International Working Group for Treatment Optimization in MS. A recommended treatment algorithm in relapsing multiple sclerosis: report of an international consensus meeting. Eur. J. Neurol. 13(1), 61–71 (2006).
  • Cavaletti G, Cavalletti E, Crippa L et al. Pixantrone (BBR2778) reduces the severity of experimental allergic encephalomyelitis. J. Neuroimmunol. 151(1–2), 55–65 (2004).
  • Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N, Sawyer DB. Anthracycline cardiotoxicity: from bench to bedside. J. Clin. Oncol. 26(22), 3777–3784 (2008).
  • Salvatorelli E, Guarnieri S, Menna P et al. Defective one- or two-electron reduction of the anticancer anthracycline epirubicin in human heart. Relative importance of vesicular sequestration and impaired efficiency of electron addition. J. Biol. Chem. 281(16), 10990–11001 (2006).
  • Hacker M, McKennon M, Singer JW. Lack of iron binding by pixantrone is associated with reduced production of reactive oxygen species and myoctye cytotoxicity in vitro. Blood 114, Abstract 4806 (2009).
  • Vásquez-Vivar J, Martasek P, Hogg N, Masters BS, Pritchard KA Jr, Kalyanaraman B. Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin. Biochemistry 36(38), 11293–11297 (1997).
  • Deng S, Kruger A, Kleschyov AL, Kalinowski L, Daiber A, Wojnowski L. Gp91phox-containing NAD(P)H oxidase increases superoxide formation by doxorubicin and NADPH. Free Radic. Biol. Med. 42(4), 466–473 (2007).
  • Rummel MJ, Niederle N, Maschmeyer G et al. Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): updated results from the StiL NHL1 study. J. Clin. Oncol. 30, Abstract 3 (2012).
  • Hortobágyi GN. Anthracyclines in the treatment of cancer. An overview. Drugs 54(Suppl. 4), 1–7 (1997).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.